Healthcare distributor Cencora (NYSE: COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAAP profit of $4.48 per share was 3% above analysts’ consensus estimates.
Is now the time to buy Cencora? Find out by accessing our full research report, it’s free.
Cencora (COR) Q2 CY2026 Highlights:
- Revenue: $84.75 billion vs analyst estimates of $84.43 billion (5.1% year-on-year growth, in line)
- Adjusted EPS: $4.48 vs analyst estimates of $4.35 (3% beat)
- Management slightly raised its full-year Adjusted EPS guidance to $17.85 at the midpoint
- Operating Margin: 1.3%, in line with the same quarter last year
- Free Cash Flow was $2.43 billion, up from -$73.97 million in the same quarter last year
- Market Capitalization: $59.59 billion
Company Overview
Formerly known as AmerisourceBergen until its 2023 rebranding, Cencora (NYSE: COR) is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services.
Revenue Growth
A company’s long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Cencora’s sales grew at a decent 10.2% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Cencora’s annualized revenue growth of 8.3% over the last two years is below its five-year trend, but we still think the results were respectable. 
Cencora also breaks out the revenue for its most important segment, US Healthcare. Over the last two years, Cencora’s US Healthcare revenue averaged 6.5% year-on-year growth. This segment has lagged the company’s overall sales. 
This quarter, Cencora grew its revenue by 5.1% year on year, and its $84.75 billion of revenue was in line with Wall Street’s estimates.
Looking ahead, sell-side analysts expect revenue to grow 5.7% over the next 12 months, a slight deceleration versus the last two years. We still think its growth trajectory is satisfactory given its scale and suggests the market is forecasting success for its products and services.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Adjusted Operating Margin
Cencora’s adjusted operating margin has generally stayed the same over the last 12 months, averaging 1.3% over the last five years. This profitability was lousy for a healthcare business and caused by its suboptimal cost structure.
Analyzing the trend in its profitability, Cencora’s adjusted operating margin might have fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.
In Q2, Cencora generated an adjusted operating margin profit margin of 1.3%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Cencora’s EPS grew at 14.4% compounded annual growth rate over the last five years, higher than its 10.2% annualized revenue growth. However, this alone doesn’t tell us much about its business quality because its adjusted operating margin didn’t improve.
We can take a deeper look into Cencora’s earnings quality to better understand the drivers of its performance. A five-year view shows that Cencora has repurchased its stock, shrinking its share count by 7.2%. This tells us its EPS outperformed its revenue not because of increased operational efficiency but financial engineering, as buybacks boost per share earnings. 
In Q2, Cencora reported adjusted EPS of $4.48, up from $4 in the same quarter last year. This print beat analysts’ estimates by 3%. Over the next 12 months, Wall Street expects Cencora’s full-year EPS to grow 12% from $17.15 to $19.21.
Key Takeaways from Cencora’s Q2 Results
It was good to see Cencora beat analysts’ EPS expectations this quarter. Zooming out, we think this was a decent quarter. The stock traded up 2.5% to $314.04 immediately following the results.
Big picture, is Cencora a buy here and now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
